Divine Formulations Profile
Key Indicators
- Authorised Capital ₹ 3.75 Cr
as on 16-11-2024
- Paid Up Capital ₹ 3.74 Cr
as on 16-11-2024
- Company Age 24 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 7.40 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit -317.85%
(FY 2023)
- Ebitda -226.79%
(FY 2023)
- Net Worth -65.01%
(FY 2023)
- Total Assets -0.11%
(FY 2023)
About Divine Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.75 Cr and a paid-up capital of Rs 3.74 Cr.
The company has closed loans amounting to ₹7.40 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Priyanka Tayal and Mukesh Tayal serve as directors at the Company.
- CIN/LLPIN
U24230MH2000PTC191118
- Company No.
191118
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Feb 2000
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Divine Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyanka Tayal  | Director | 22-Feb-2024 | Current |
| Mukesh Tayal | Director | 05-Feb-2024 | Current |
Financial Performance of Divine Formulations.
Divine Formulations Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 317.85% decrease in profit. The company's net worth observed a substantial decline by a decrease of 65.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Divine Formulations?
In 2023, Divine Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tayal Inorganic Private LimitedActive 26 years 2 monthsPriyanka Tayal and Mukesh Tayal are mutual person
Digmore Autotech Private LimitedActive 3 years 2 monthsPriyanka Tayal and Mukesh Tayal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 18 Mar 2005 | ₹7.35 Cr | Satisfied |
State Bank Of India Creation Date: 22 Dec 2003 | ₹0.50 M | Satisfied |
How Many Employees Work at Divine Formulations?
Unlock and access historical data on people associated with Divine Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Divine Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Divine Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
